

A coding VKORC1 Asp36Tyr polymorphism predisposes

Blood

109, 2477-2480

DOI: [10.1182/blood-2006-08-038984](https://doi.org/10.1182/blood-2006-08-038984)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Genomics and Proteomics in Venous Thromboembolism: Building a Bridge toward a Rational Personalized Medicine Framework. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 759-770.	1.5	12
2	Use of genetic and nongenetic factors in warfarin dosing algorithms. <i>Pharmacogenomics</i> , 2007, 8, 851-861.	0.6	58
3	Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. <i>Pharmacogenomics</i> , 2007, 8, 487-496.	0.6	29
4	Pharmacogenetics of oral anticoagulants: the opportunity for individualized drug treatment of greater safety. <i>Personalized Medicine</i> , 2007, 4, 413-421.	0.8	2
5	Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles. <i>Thrombosis and Haemostasis</i> , 2007, 98, 570-578.	1.8	67
6	Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 45-51.	1.0	216
7	Oral anticoagulants: Pharmacogenetics. <i>Blood Reviews</i> , 2008, 22, 127-140.	2.8	53
8	Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1052-1057.	1.8	118
9	Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations. <i>American Journal of Human Genetics</i> , 2008, 82, 495-500.	2.6	122
10	A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1224-1226.	1.9	24
11	Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1436-1439.	1.9	39
12	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1445-1449.	1.9	14
13	Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1663-1670.	1.9	58
14	Managing oral anticoagulation therapy: improving clinical outcomes. A review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 581-590.	0.7	20
15	Warfarin Pharmacogenetics. <i>Pharmacotherapy</i> , 2008, 28, 1084-1097.	1.2	120
16	Pharmacogenetics of Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2008, 47, 565-594.	1.6	94
17	The Vitamin K Cycle. <i>Vitamins and Hormones</i> , 2008, 78, 35-62.	0.7	143
18	Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. <i>Genetics in Medicine</i> , 2008, 10, 139-150.	1.1	210

#	ARTICLE	IF	CITATIONS
19	New Issues in Oral Anticoagulants. Hematology American Society of Hematology Education Program, 2008, 2008, 259-265.	0.9	19
20	Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose. American Journal of Clinical Pathology, 2008, 129, 876-883.	0.4	74
21	Shifting paradigms in the pharmacogenetics of warfarin. Pharmacogenomics, 2008, 9, 1373-1375.	0.6	4
22	Effects of <i>CYP2C9</i> and <i>VKORC1</i> on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics, 2008, 9, 1237-1250.	0.6	38
23	Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics, 2008, 9, 1331-1346.	0.6	54
24	In situ identification of allospecific B cells using pentamers. Blood, 2008, 111, 3904-3905.	0.6	3
25	<i>VKORC1</i> Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood, 2008, 111, 3903-3904.	0.6	38
26	Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now. Annals of Internal Medicine, 2009, 151, 270.	2.0	42
27	Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics, 2009, 10, 1905-1913.	0.6	70
28	Pharmacogenetics of vitamin K antagonists: useful or hype?. Clinical Chemistry and Laboratory Medicine, 2009, 47, 503-15.	1.4	31
29	Vitamin K epoxide reductase complex 1 (<i>VKORC1</i>) haplotypes in healthy Hungarian and Roma population samples. Pharmacogenomics, 2009, 10, 1025-1032.	0.6	19
30	10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics, 2009, 10, 1955-1965.	0.6	20
31	Pharmacogenetics in Hemostasis: Friend or Foe?. Seminars in Thrombosis and Hemostasis, 2009, 35, 042-049.	1.5	5
32	<i>CYP2C9</i> *8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics, 2009, 10, 1243-1255.	0.6	100
33	Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report. European Journal of Clinical Pharmacology, 2009, 65, 1265-1266.	0.8	3
34	Vascular Cognitive Impairment. , 2009, , 2172-2172.		0
35	Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine, 2009, 360, 753-764.	13.9	1,375
36	Validation of Clinical Testing for Warfarin Sensitivity. Journal of Molecular Diagnostics, 2009, 11, 216-225.	1.2	53

#	ARTICLE	IF	CITATIONS
37	Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clinic Proceedings, 2009, 84, 1079-1094.	1.4	115
38	Importance of cell-procurement methods in transforming personalized cancer treatment from concept to reality. Personalized Medicine, 2009, 6, 33-43.	0.8	2
39	Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. PLoS Medicine, 2009, 6, e1000029.	3.9	780
40	Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 2009, 113, 3925-3930.	0.6	79
41	VKORC1 Pharmacogenomics Summary. Pharmacogenetics and Genomics, 2010, 20, 642-644.	0.7	100
42	Distribution of CYP2C9 and VKORC1 Risk Alleles for Warfarin Sensitivity and Resistance in the Israeli Population. Current Drug Safety, 2010, 5, 190-193.	0.3	13
43	Pharmacogenetics of Oral Anticoagulant Therapy. Current Pharmaceutical Design, 2010, 16, 187-203.	0.9	45
44	Will there be a role for genotyping in warfarin therapy?. Current Opinion in Hematology, 2010, 17, 439-443.	1.2	7
45	VKORC1 \sim 1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. European Journal of Clinical Pharmacology, 2010, 66, 591-598.	0.8	22
46	Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European Journal of Clinical Pharmacology, 2010, 66, 755-774.	0.8	60
47	VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. European Journal of Clinical Pharmacology, 2010, 66, 1217-1227.	0.8	36
48	Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of Thrombosis and Haemostasis, 2010, 8, 1018-26.	1.9	57
49	<i>CYP4F2</i> rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. British Journal of Clinical Pharmacology, 2010, 70, 234-240.	1.1	64
50	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. Personalized Medicine, 2010, 7, 319-325.	0.8	5
51	Pharmacogenetic Impact of VKORC1 and CYP2C9 Allelic Variants on Warfarin Dose Requirements in a Hispanic Population Isolate. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 83-90.	0.7	18
52	Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 297-301.	3.3	58
53	Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal of Molecular Diagnostics, 2010, 12, 283-291.	1.2	62
54	Pharmacogenetics of Warfarin. Annual Review of Medicine, 2010, 61, 63-75.	5.0	92

#	ARTICLE	IF	CITATIONS
55	A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. <i>Thrombosis Research</i> , 2010, 125, e259-e264.	0.8	50
56	Application of Akaike information criterion to evaluate warfarin dosing algorithm. <i>Thrombosis Research</i> , 2010, 126, 183-190.	0.8	28
57	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. <i>Thrombosis Research</i> , 2010, 126, e206-e210.	0.8	14
58	Patient Factors That Influence Warfarin Dose Response. <i>Journal of Pharmacy Practice</i> , 2010, 23, 194-204.	0.5	37
59	Pharmacogenomic Testing in Current Clinical Practice. , 2011, , .		2
60	Genetic Testing in Clinical Practice. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011, 17, 316-325.	0.4	0
63	Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 109-118.	1.9	85
64	Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2120-2122.	1.9	20
65	Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1301-1308.	0.8	21
66	Risk modeling strategies for pharmacogenetic studies. <i>Pharmacogenomics</i> , 2011, 12, 397-410.	0.6	1
67	Novel Insight into the Mechanism of the Vitamin K Oxidoreductase (VKOR). <i>Journal of Biological Chemistry</i> , 2011, 286, 7267-7278.	1.6	74
68	Current challenges in personalizing warfarin therapy. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 349-362.	1.3	13
69	Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses. <i>Clinical Medicine and Research</i> , 2011, 9, 119-124.	0.4	9
70	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 893-904.	1.5	53
71	Optimization of warfarin dose by population-specific pharmacogenomic algorithm. <i>Pharmacogenomics Journal</i> , 2012, 12, 306-311.	0.9	46
72	CYP2C9 and VKORC1 Polymorphisms Are Differently Distributed in the Brazilian Population According to Self-Declared Ethnicity or Genetic Ancestry. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 957-963.	0.3	25
74	Clinical Pharmacogenomics of Warfarin and Clopidogrel. <i>Journal of Pharmacy Practice</i> , 2012, 25, 428-438.	0.5	13
75	Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. <i>Clinical Biochemistry</i> , 2012, 45, 397-401.	0.8	17

#	ARTICLE	IF	CITATIONS
76	Therapeutic Dosing of Acenocoumarol: Proposal of a Population Specific Pharmacogenetic Dosing Algorithm and Its Validation in North Indians. PLoS ONE, 2012, 7, e37844.	1.1	39
77	VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity. Journal of Thrombosis and Haemostasis, 2012, 10, 2535-2543.	1.9	49
78	Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thrombosis and Haemostasis, 2012, 108, 781-788.	1.8	20
79	Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics, 2012, 13, 869-878.	0.6	15
80	Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e44064.	1.1	142
81	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Archives of Toxicology, 2013, 87, 407-420.	1.9	50
82	CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European Journal of Clinical Pharmacology, 2013, 69, 789-797.	0.8	29
83	Pharmacogenomics of warfarin in populations of African descent. British Journal of Clinical Pharmacology, 2013, 75, 334-346.	1.1	34
84	VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thrombosis and Haemostasis, 2013, 109, 1045-1050.	1.8	24
87	Pharmacogenetics of Oral Anticoagulants. , 2013, , 435-467.		0
88	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thrombosis and Haemostasis, 2013, 110, 1087-1107.	1.8	347
90	Pharmacogenomics of Warfarin. , 2014, , 497-507.		0
91	Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. Pharmacogenomics, 2014, 15, 1125-1132.	0.6	6
92	Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions, 2014, 29, 221-233.	0.3	14
93	Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and Genomics, 2014, 24, 501-513.	0.7	10
94	The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. Journal of Applied Genetics, 2014, 55, 163-171.	1.0	5
95	Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Molecular Diagnosis and Therapy, 2014, 18, 675-683.	1.6	25
96	Identification of VKORC1 genotype leading to resistance to tecarfarin. Journal of Clinical Pharmacology, 2014, 54, 896-900.	1.0	3

#	ARTICLE	IF	CITATIONS
97	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 428-436.	1.0	64
98	High prevalence of <i>VKORC1*3</i> (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol. <i>Drug Discoveries and Therapeutics</i> , 2015, 9, 404-410.	0.6	5
99	Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. <i>Pharmacogenomics</i> , 2015, 16, 865-876.	0.6	36
100	Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. <i>Pharmacogenomics Journal</i> , 2015, 15, 101-108.	0.9	15
102	Comparative Biology of the Resistance to Vitamin K Antagonists: An Overview of the Resistance Mechanisms. , 0, , .		7
104	Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2016, 55, 419-436.	1.6	13
105	PGWD: Integrating Personal Genome for Warfarin Dosing. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2016, 8, 23-27.	2.2	0
106	Adaptative evolution of the <i>Vkorc1</i> gene in <i>Mus musculus domesticus</i> is influenced by the selective pressure of anticoagulant rodenticides. <i>Ecology and Evolution</i> , 2017, 7, 2767-2776.	0.8	36
107	Anticoagulation therapy for a LVAD patient with acquired warfarin resistance. <i>Journal of Artificial Organs</i> , 2017, 20, 260-262.	0.4	6
108	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 747-753.	0.3	14
109	Genetic variation in human drug-related genes. <i>Genome Medicine</i> , 2017, 9, 117.	3.6	104
110	Personalized Medicine in Cardiovascular Disease. , 2017, , 457-471.		1
111	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
112	Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. <i>Genes</i> , 2018, 9, 578.	1.0	27
114	Gene Therapy and Genomic Application in Heart Disease. <i>Translational Bioinformatics</i> , 2018, , 337-374.	0.0	0
115	Utilizing Whole-Exome Sequencing to Characterize the Phenotypic Variability of Sickle Cell Disease. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 561-567.	0.3	29
116	Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. <i>Journal of Medical Genetics</i> , 2018, 55, 617-627.	1.5	24
117	Pharmacogenetic Warfarin Dosing Algorithms: Validity in Egyptian Patients. <i>Acta Haematologica</i> , 2018, 139, 255-262.	0.7	5

#	ARTICLE	IF	CITATIONS
118	Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. <i>Blood</i> , 2018, 132, 1974-1984.	0.6	24
119	Oral Anticoagulant Therapy—When Art Meets Science. <i>Journal of Clinical Medicine</i> , 2019, 8, 1747.	1.0	13
120	Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 15-22.	0.4	8
121	Validation of Pharmacogenetic Testing Before Initiation of Warfarin Therapy. <i>University Heart Journal</i> , 2019, 15, 74-78.	0.0	0
122	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. <i>Pharmacogenomics Journal</i> , 2020, 20, 104-113.	0.9	13
123	Recommendations for Clinical Warfarin Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 847-859.	1.2	39
124	Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population. <i>Scientific Reports</i> , 2020, 10, 5652.	1.6	9
125	Role of Genetic Variations in the Hepatic Handling of Drugs. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2884.	1.8	15
126	Personalized medicine in cardiovascular disease: review of literature. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1793-1805.	0.8	8
127	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. <i>PLoS ONE</i> , 2013, 8, e64469.	1.1	16
128	Prothrombin Gene G20210A Mutation in Acute Deep Venous Thrombosis Patients with Poor Response to Warfarin Therapy. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 147-151.	0.6	8
129	Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. <i>Croatian Medical Journal</i> , 2019, 60, 212-220.	0.2	10
130	Genetic variant in the promoter region of microRNA-137 reduces the warfarin maintenance dose in patients with atrial fibrillation. <i>Molecular Medicine Reports</i> , 2019, 19, 5361-5367.	1.1	1
131	Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos. <i>Biomedica</i> , 2010, 30, 410.	0.3	6
133	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 2009, , 293-340.		2
134	The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs. , 2011, , 117-138.		0
135	Combined effect of CYP2C9 and VKORC1 polymorphisms on warfarin maintenance dose in Omani patients. <i>Open Journal of Genetics</i> , 2012, 02, 184-189.	0.1	1
136	Current Status of Pharmacogenetics in Antithrombotic Drug Therapy. , 0, ,		0

#	ARTICLE	IF	CITATIONS
139	Clinical pharmacogenetics. , 2022, , 189-212.		0
140	PGWD: integrating personal genome for warfarin dosing. Interdisciplinary Sciences, Computational Life Sciences, 2015, , .	2.2	0
141	Pharmacogenetics aspects of oral anticoagulants therapy. Journal of Medicine and Life, 2015, 8, 171-5.	0.4	9
142	Left Ventricular Assist Device Pump Thrombosis in a Patient Treated with Apixaban. American Journal of Case Reports, 2021, 22, e934787.	0.3	4
143	Warfarin Dosing in Patients With <i>CYP2C9</i> *5 Variant Alleles. Clinical Pharmacology and Therapeutics, 2022, 111, 950-955.	2.3	7
144	Cross-ethnic analysis of common gene variants in hemostasis show lopsided representation of global populations in genetic databases. BMC Medical Genomics, 2022, 15, 69.	0.7	0
145	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
146	A Systematic Review of Polygenic Models for Predicting Drug Outcomes. Journal of Personalized Medicine, 2022, 12, 1394.	1.1	4
147	Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state. Blood Advances, 2023, 7, 2271-2282.	2.5	2
148	A case of pulmonary embolism with bad warfarin anticoagulant effects caused by <i>E. coli</i> infection. Open Life Sciences, 2023, 18, .	0.6	1
149	Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP). Pharmacogenomics Journal, 0, , .	0.9	0
150	Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population. Drug Metabolism and Personalized Therapy, 2023, .	0.3	2
153	Pharmacogenomics in cardiovascular disease. , 2024, , 623-642.		0